Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Next Generation StaR TREC
2025-522955-25-00Phase 4Authorised
- Sponsor
- Region Västra Götaland
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of capecitabine in rectal cancer (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Clinical complete response at 1 year in non-operative cohort. Planned start Jan 2026; status: authorised.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2025-522955-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522955-25-00.